Abstract
Adalimumab is a recombinant fully human monoclonal antibody targeting soluble and transmembrane TNF alpha. It is approved for the treatment of immune-mediated rheumatic, gastroenterological, dermatological, and ophthalmological conditions and this therapeutic versatility has made it the top-selling drug worldwide since 2012. Not surprisingly, following the patent expiration of the originator drug, biopharmaceutical companies invested in the development of biosimilar versions of adalimumab and six have already received marketing authorisation: ABP 501, GP2017, and BI 695501 in Europe and in the USA (though the manufacturer of the latter requested authorisation withdrawal in Europe), and SB5, FKB327, and MSB11022 in Europe. This manuscript reviews published data on approved adalimumab biosimilars, including analytical and biofunctional results from preclinical assessments; pharmacokinetics after administration in healthy subjects (Phase I trials); and efficacy, safety, and immunogenicity from pivotal (Phase III) clinical trials. Data on switching from reference adalimumab to biosimilars, and predicted cost-savings from available budget impact models, will also be addressed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
